ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2021

Abstract Number: 0115

Rheumatic Disease Management by Resilient Rheumatology Providers in COVID-19 Pandemic: A National Veterans Affairs Follow-up Survey Assessing Provider Practice and Views Since June 2020

Jasvinder Singh1, John Richards2, Elizabeth Chang3, Amy Joseph4 and Bernard Ng5, 1University of Alabama at Birmingham, Birmingham, AL, 2Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 3Phoenix Veterans Affairs Medical Center (VAMC), Phoenix, AZ, 4Washington University / St. Louis VA, St Louis, MO, 5VA Puget Sound HCS, Seattle, WA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2021

Keywords: Access to care, COVID-19, resilience, rheumatologist, telemedicine

Session Information

Date: Saturday, November 6, 2021

Title: Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: To assess the experience, current practices, views and opinions of rheumatology providers at Veterans Affairs (VA) facilities for the care of the patients with rheumatic disease during the COVID-19 pandemic in 2020-21

Methods: We performed an anonymized cross-sectional survey to assess VA rheumatology provider perspective on COVID-19 healthcare issues and resilience, from November 2020 to January 2021, and compare practices to the baseline survey from April-May 2020 (Singh JA, ACR 2020).

Results: Of the 153 eligible VA rheumatologists, 114 (75%) completed the survey. The mean CD-RISC2 score was 6.8 (SD, 1.11; range 0-8; higher=more resilient), higher than the original survey score of 6.35 (SD, 1.26; p=0.004 and p=0.008, respectively). The proportion of rheumatology providers who chose telephone or VVC as the best modality for follow-up of established patients varied widely across rheumatic diseases as follows (Figure 1): (1) gout, osteoporosis, polymyalgia rheumatica, or osteoarthritis (OA), 90-100%; (2) stable rheumatoid arthritis (RA), stable spondyloarthritis (SpA) or stable lupus, scleroderma or vasculitis, 73-88%; (3) local musculoskeletal conditions or tendinitis, 45-46%; (4) lupus, scleroderma, vasculitis, RA or SpA with immunosuppressive, glucocorticoid or disease-modifying antirheumatic disease drug (DMARD)/biologic) changes, 9-20% (Figure 1).

Compared to the original survey, the use of telephone visits was lower by 10-20%, while VVC and in-person were higher by about 10%.

Comfort with Technology: Established Patients. Provider comfort with technology was essentially unchanged compared to the original survey: (1) telephone visits, 82%; (2) VVC visits, 63%. 33% were comfortable with CVT visits, with no previous comparator question (Figure 2). New patients. Provider comfort with technology increased compared to the original survey: telephone visits, 40% vs. 25% (p=0.019); VVC visits, 47% vs. 34% (p=0.051; Figure 2).

Comfort with the Quality of Outpatient Visits and Improvement in Comfort Since June 2020 (no previous data/comparator): Providers comfort with the quality of clinical encounter for established vs. new patients was as follows (Figure 3): (1) telephone, 63% vs. 27%; (2) VVC, 63% vs. 47%; and (3) CVT 32% vs. 27%. Improvement in comfort with the quality of the clinical encounter since June 2020 for established vs. new patients was as follows: telephone, 66% vs. 46%; VVC, 67% vs. 58%; and CVT, 31% vs. 27%.

Adjusted for age, sex, and ethnicity, high provider resilience was significantly associated with a higher odds ratio (OR) of comfort with technology and comfort with the quality of the VVC visit: (1) established patient, 1.71 (95% CI, 0.67-4.40) and 4.13 (95% CI, 1.49-11.44); (2) new patient, 2.79 (95% CI, 1.11-7.05); and 2.69 (95% CI, 1.06-6.82), respectively.

Conclusion: Utilization of and comfort with video visits during the COVID-19 pandemic increased over time among VA rheumatology providers, also associated with provider resilience


Disclosures: J. Singh, Crealta/Horizon, 2, Medisys, 2, Fidia, 2, PK Med, 2, Two labs Inc, 2, Adept Field Solutions, 2, Clinical Care options, 2, Clearview healthcare partners, 2, Putnam associates, 2, Focus forward, 2, Navigant consulting, 2, Spherix, 2, MedIQ, 2, Jupiter Life Science, 2, UBM LLC, 2, Trio Health, 2, Medscape, 2, WebMD, 2, Practice Point communications, 2, the National Institutes of Health, 2, the American College of Rheumatology, 2, TPT Global Tech, 11, Vaxart pharmaceuticals, 11, Charlotte’s Web Holdings, Inc., 11, Amarin pharmaceuticals, 11, Viking pharmaceuticals, 11, Moderna pharmaceuticals, 11, speaker’s bureau of Simply Speaking, 6, member of the executive of Outcomes Measures in Rheumatology, 4; J. Richards, None; E. Chang, None; A. Joseph, None; B. Ng, None.

To cite this abstract in AMA style:

Singh J, Richards J, Chang E, Joseph A, Ng B. Rheumatic Disease Management by Resilient Rheumatology Providers in COVID-19 Pandemic: A National Veterans Affairs Follow-up Survey Assessing Provider Practice and Views Since June 2020 [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/rheumatic-disease-management-by-resilient-rheumatology-providers-in-covid-19-pandemic-a-national-veterans-affairs-follow-up-survey-assessing-provider-practice-and-views-since-june-2020/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatic-disease-management-by-resilient-rheumatology-providers-in-covid-19-pandemic-a-national-veterans-affairs-follow-up-survey-assessing-provider-practice-and-views-since-june-2020/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology